{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-031597","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.827335+00:00","generated_at":"2026-06-21T07:53:08.088460+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arrowhead Pharmaceuticals raises ~$250M via equity offering of 7.8M shares through Jefferies","bullets":["Entered Open Market Sale Agreement with Jefferies LLC to sell up to 7,807,620 shares of common stock.","Estimated gross proceeds of ~$250 million after discounts, commissions, and expenses.","Offering closed on December 2, 2022; shares issued under shelf registration statement on Form S-3.","Company agreed to indemnify Jefferies against certain liabilities under the Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-031597","json":"https://secwatch.observer/filing/0001628280-22-031597.json","markdown":"https://secwatch.observer/filing/0001628280-22-031597.md","text":"https://secwatch.observer/filing/0001628280-22-031597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/0001628280-22-031597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/arwr-20221202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:53:08.088460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b8a504b7464bfc0984ba8e07a52651c2aa5d624","claim":"ARROWHEAD PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at approximately $250 million (effective 2022-12-02).","evidence_excerpt":"On December 2, 2022, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an open market sale agreement (the “Open Market Sale Agreement”) with Jefferies LLC (the \"Agent\"), pursuant to which the Company agreed to issue and sell up to 7,807,620 shares of common stock (the “Shares”), par value $0.001 per share (the “Common Stock”). The Company estimates that gross proceeds from the offering will be approximately $250 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/0001628280-22-031597-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"approximately $250 million"},{"label":"Effective","value":"2022-12-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}